Cisplatin-induced therapy-related myelodysplastic syndrome during avelumab maintenance therapy for metastatic urothelial carcinoma.

IF 0.5 Q4 ONCOLOGY

International Cancer Conference Journal Pub Date : 2025-01-24 eCollection Date: 2025-04-01 DOI:10.1007/s13691-024-00735-w

Yusuke Sugino, Taketomo Nishikawa, Sota Inaba, Shunsuke Owa, Momoko Kato, Shinichiro Higashi, Takeshi Sasaki, Satoru Masui, Kouhei Nishikawa, Akihide Nakamura, Miki Usui, Takahiro Inoue

引用次数: 0

Abstract

A 64 year-old man underwent a radical cystectomy for muscle-invasive bladder cancer. Five years later, lung and mediastinal lymph node metastases were detected. After 15 courses of gemcitabine and cisplatin for metastatic urothelial carcinoma, the patient was switched to avelumab maintenance therapy. During this period, the patient developed a therapy-related myelodysplastic syndrome, leading to difficulty in continuing treatment. Therapy-related myelodysplastic syndrome is a dose-dependent complication that can develop several years after chemotherapy or radiotherapy. Therefore, excessive cisplatin administration should be avoided.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

International Cancer Conference Journal ONCOLOGY-

自引率

14.30%

发文量

期刊介绍： This online-only journal publishes original case reports on all types of cancer. In particular, we welcome not only case reports of educational value in the diagnosis and treatment of cancers, but also reports on molecularly analyzed cancer cases, including gene mutations, gene fusions, gene expression, and changes in copy number, regardless of their known clinical significance. Assessing the molecular analysis of a tumor usually requires a “cancer conference” in which experts from various fields discuss it. Even if the authors and their respective “cancer conference” were unable to determine the clinical significance of molecular changes at the time of submission and publication, their data may provide evidence that will help the scientific community develop precision medicine solutions in the future. We welcome case reports with reviews of the literature on similar cases, as they are more useful and valuable to readers than are reports of rare cases. International Cancer Conference Journal is the official publication of the Japan Society of Clinical Oncology (JSCO). - Presents an online-only collection of original case reports on all types of cancer - In particular, welcomes molecularly analyzed cancer cases - The Official Publication of the Japan Society of Clinical Oncology (JSCO)